Pfizer exceeds Q1 earnings expectations despite vaccine sales decline.
TL;DR Summary
Pfizer's Q1 earnings beat estimates with non-GAAP EPS of $1.23 and revenue of $18.3B, driven by strong sales of COVID-19 vaccines Comirnaty and Paxlovid. The company reaffirmed its full-year 2023 financial guidance, with expected revenues of $67.0 billion to $71.0 billion and adjusted diluted EPS of $3.25 to $3.45. Pfizer expects Comirnaty and Paxlovid to generate $7.1 billion in Q1 2023, with Comirnaty revenue expected to reach $13.5 billion and Paxlovid revenue expected to reach $8 billion in full-year 2023.
- Pfizer beats Q1 top and bottom line estimates; reaffirms FY23 outlook Seeking Alpha
- Pfizer earnings and revenue top expectations despite Covid vaccine sales decline CNBC
- Pfizer Stock Jumps After Sales Beat. There's More Good News From Earnings. Barron's
- Pfizer tops Q1 forecasts; vaccine sales slide as expected Yahoo Finance
- Pfizer's Earnings Fall With Cooling Demand for Covid Products The Wall Street Journal
Reading Insights
Total Reads
1
Unique Readers
12
Time Saved
0 min
vs 1 min read
Condensed
27%
109 → 80 words
Want the full story? Read the original article
Read on Seeking Alpha